RADX Radiopharm Theranostics Ltd


$ 4.93 $ -0.21 (-4.01 %)    

Monday, 03-Nov-2025 10:29:59 EST
QQQ $ 631.67 $ -3.53 (-0.56 %)
DIA $ 473.69 $ -2.56 (-0.54 %)
SPY $ 682.57 $ -3.08 (-0.45 %)
TLT $ 89.48 $ -0.17 (-0.19 %)
GLD $ 368.20 $ -0.50 (-0.14 %)
$ 5.26
$ 5.03
$ 4.81 x 100
$ 5.06 x 100
$ 5.01 - $ 5.03
$ 3.50 - $ 50.82
16,239
na
na
$ 0.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from s...

Core News & Articles

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 mil...

Core News & Articles

- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceu...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, &, ldquo, Radiopharm&, rdquo, or the &, ldquo, Company&, rdquo,...

Core News & Articles

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and an...

Core News & Articles

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profileEthics approval and Phase 1...

Core News & Articles

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION